Subcutaneous Administration of Amifostine During Fractionated Radiotherapy: A Randomized Phase II Study

Abstract

Subcutaneous administration of amifostine is well tolerated, effectively reduces radiotherapy's early toxicity, and prevents delays in radiotherapy. The subcutaneous route is much simpler and saves time compared with the intravenous route of administration and can be safely and effectively applied in the daily, busy radiotherapy practice.